These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1833046)

  • 1. Sequentially administered ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors.
    Fromm GL; Freedman RS; Fritsche HA; Atkinson EN; Scott W
    Cancer; 1991 Nov; 68(9):1885-9. PubMed ID: 1833046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study.
    Freedman RS; Saul PB; Edwards CL; Jolles CJ; Gershenson DM; Jones LA; Atkinson EN; Dana WJ
    Cancer Treat Rep; 1986 Mar; 70(3):369-73. PubMed ID: 2937533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced endometrial adenocarcinoma with cyclic sequential ethinyl estradiol and medroxyprogesterone acetate.
    Tatman JL; Freedman RS; Scott W; Atkinson EN
    Eur J Cancer Clin Oncol; 1989 Nov; 25(11):1619-21. PubMed ID: 2531671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of sequential treatment with ethynyloestradiol and medroxyprogesterone acetate on oestrogen and progestogen receptors in breast cancer.
    Ghilchik M; Shaikh NA; Beranek PA; Reed MJ; Braunsberg H
    J Steroid Biochem; 1989; 34(1-6):403-5. PubMed ID: 2533948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential cyclic combined hormonal therapy for metastatic breast cancer.
    Hortobagyi GN; Hug V; Buzdar AU; Kau SW; Holmes FA; Fritsche HA
    Cancer; 1989 Sep; 64(5):1002-6. PubMed ID: 2527085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen and progesterone receptor titers in primary epithelial ovarian carcinomas.
    Jones LA; Edwards CL; Freedman RS; Tan MT; Gallager HS
    Int J Cancer; 1983 Nov; 32(5):567-71. PubMed ID: 6315602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined chemo- and hormone-therapy in advanced ovarian carcinoma--theoretical, experimental foundations and clinical results].
    Sevelda P
    Wien Klin Wochenschr Suppl; 1990; 183():3-29. PubMed ID: 2145702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.
    Hamerlynck JV; Maskens AP; Mangioni C; van der Burg ME; Wils JA; Vermorken JB; Rotmensz N
    Gynecol Oncol; 1985 Nov; 22(3):313-6. PubMed ID: 2998957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethinyl estradiol and medroxyprogesterone treatment in advanced breast cancer: a pilot study.
    Pellegrini A; Massidda B; Mascia V; Ionta MT; Lippi MG; Muggiano A; Carboni E; Robustelli della Cuna G; Bernardo G; Strada MR; Pavesi L
    Cancer Treat Rep; 1981; 65(1-2):135-6. PubMed ID: 7226163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
    Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
    J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer.
    Nemoto T; Patel JK; Rosner D; Dao TL; Halvorson H
    J Surg Oncol; 1989 Aug; 41(4):226-9. PubMed ID: 2526907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro.
    Geisinger KR; Berens ME; Duckett Y; Morgan TM; Kute TE; Welander CE
    Cancer; 1990 Mar; 65(5):1055-61. PubMed ID: 2137365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy.
    Mangioni C; Franceschi S; La Vecchia C; D'Incalci M
    Gynecol Oncol; 1981 Dec; 12(3):314-8. PubMed ID: 6458544
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclic hormonal treatment in ovarian cancer. A phase-II trial.
    Jakobsen A; Bertelsen K; Sell A
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):915-6. PubMed ID: 2959486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
    Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
    Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of tamoxifen-medroxyprogesterone sequential therapy on estrogen and progesterone receptor contents of breast cancer.
    Noguchi S; Yamamoto H; Inaji H; Imaoka S; Koyama H
    Jpn J Cancer Res; 1989 Mar; 80(3):244-8. PubMed ID: 2524460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
    Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
    J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose medroxyprogesterone in the treatment of advanced therapy-resistant prostatic carcinoma.
    Johansson JE; Lingårdh G
    Eur Urol; 1985; 11(1):9-10. PubMed ID: 3157573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.